Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02980874 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

460

Enrollment

INDUSTRY

Sponsor class

Stopped Primary, 8-week efficacy endpoint not achieved. No additional benefit for subjects receiving a corticosteroid together with an intravitreal anti-VEGF agent.

Conditions

Macular Edema
Retinal Vein Occlusion

Interventions

DRUG: suprachoroidal CLS-TA
DRUG: suprachoroidal sham
DRUG: IVT aflibercept

Sponsor

Clearside Biomedical, Inc.